Reldesemtiv is a Small Molecule owned by Cytokinetics, and is involved in 10 clinical trials, of which 8 were completed, and 2 are ongoing.

Reldesemtiv (CK-2127107) is a fast skeletal muscle troponin activator. It activates TNNC2, TNNI2 and TNNT3. Ca2+ binds to the N-terminal Ca2+ binding site of troponin C initiating a conformational change in troponin C, which catalyzes protein-protein associations activity. This activation, in turn, facilitates cross-bridge cycling, myofibrillar activation complex by increasing its sensitivity to calcium, leading to an increase in skeletal muscle contractility.

The revenue for Reldesemtiv is expected to reach a total of $542m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Reldesemtiv NPV Report.

Reldesemtiv is originated and owned by Cytokinetics.

Reldesemtiv Overview

Reldesemtiv (CK-2127107) is under development for the treatment of amyotrophic lateral sclerosis. The drug candidate is administered through the oral route in the form of a tablet and suspension. It is a new molecule entity that acts on fast skeletal muscle troponin activator (FSTA). It was also under development for  spinal muscular atrophy, movement disorders (frailty syndrome) in older patients and chronic obstructive pulmonary disease (COPD).

Cytokinetics Overview

Cytokinetics is a biopharmaceutical company with a focus on the discovery, development, and commercialization of muscle activators and muscle inhibitors as potential treatments for debilitating diseases wherein muscle performance is affected. The company develops small molecule drug candidates designed to affect muscle function and contractility. Cytokinetics is developing aficamten, a next-generation cardiac myosin inhibitor, to treat hypertrophic cardiomyopathy (HCM). It is also developing reldesemtiv, a fast skeletal muscle troponin activator, for the treatment of ALS patients. The company has licensing and collaboration agreements with Amgen, Ji Xing, and Astellas for advancing its drug candidates. Cytokinetics is headquartered in South San Francisco, California, the US.

The company reported revenues of (US Dollars) US$70.4 million for the fiscal year ended December 2021 (FY2021), an increase of 26.2% over FY2020. The operating loss of the company was US$186.3 million in FY2021, compared to an operating loss of US$93.9 million in FY2020. The net loss of the company was US$215.3 million in FY2021, compared to a net loss of US$127.3 million in FY2020. The company reported revenues of US$2.5 million for the third quarter ended September 2022, a decrease of 97.2% over the previous quarter.

Quick View – Reldesemtiv

Report Segments
  • Innovator
Drug Name
  • Reldesemtiv
Administration Pathway
  • Oral
Therapeutic Areas
  • Central Nervous System
  • Respiratory
Key Companies
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.